Sarah Lawrence College

DigitalCommons@SarahLawrence
Human Genetics Theses

The Joan H. Marks Graduate Program in
Human Genetics

5-2018

Adolescent Perspectives on Genetic Testing for Huntington’s
Disease
Katelyn Cooke
Sarah Lawrence College

Elizabeth Crate
Sarah Lawrence College

Ravneet Grewal
Sarah Lawrence College

Jennifer Huynh-Lim
Sarah Lawrence College

Follow this and additional works at: https://digitalcommons.slc.edu/genetics_etd
Part of the Genetics Commons

Recommended Citation
Cooke, Katelyn; Crate, Elizabeth; Grewal, Ravneet; and Huynh-Lim, Jennifer, "Adolescent Perspectives on
Genetic Testing for Huntington’s Disease" (2018). Human Genetics Theses. 43.
https://digitalcommons.slc.edu/genetics_etd/43

This Thesis - Open Access is brought to you for free and open access by the The Joan H. Marks Graduate Program
in Human Genetics at DigitalCommons@SarahLawrence. It has been accepted for inclusion in Human Genetics
Theses by an authorized administrator of DigitalCommons@SarahLawrence. For more information, please contact
alester@sarahlawrence.edu.

Adolescent Perspectives on Genetic Testing for Huntington’s Disease
Katelyn Cooke, Elizabeth Crate, Ravneet Grewal, & Jennifer Huynh-Lim
Sarah Lawrence College, Bronxville, NY

Submitted in partial completion of the Master of Science Degree at Sarah Lawrence College, May 2018.

ABSTRACT
In 2015, the American Society of Human Genetics (ASHG) released a position statement
which recommended minors to defer genetic testing for adult-onset conditions until adulthood. In
the 2016 DNA Day Essay Contest, high school students were asked to research an adult-onset
genetic disorder and use it to formulate a stance on whether they agreed or disagreed with the
position statement. Phase two of this study focused on the essays written about Huntington’s
Disease (HD). Within the HD essays, 57% chose to defer, 35% chose not to defer, and 8% did
not clearly state an opinion. Essays were analyzed using a codebook that was established in
Phase one and the top codes were further analyzed for themes. The top codes that were
thematically analyzed were “Psychological Risks to Minor”, “No Medical Benefit/Not
Preventable”, “Necessary to Plan/Prepare”, and “Genetic Testing Variability and Uncertain
Predictability.” Although many of the essays agreed to defer testing, many students cited similar
reasons, regardless of their stance.
Keywords: predictive testing, presymptomatic testing, minors, adolescents, adult onset,
ethics, perspectives, attitudes, genetic testing, Huntington’s Disease
BACKGROUND
Genetic testing in the pediatric setting is a rare occurrence outside of newborn screening.
Generally, genetic testing of minors is only done for diagnostic or immediate medical purposes;
otherwise, most professional organizations recommend that minors postpone testing until
adulthood. There are arguments in the literature both supporting and discouraging the testing of
minors for adult-onset conditions, such as Huntington’s Disease.

Current Guidelines for the Genetic Testing of Minors
A number of North American societies for genetics professionals, including the National
Society of Genetic Counseling (NSGC), the American Society of Human Genetics (ASHG), and
the American College of Medical Genetics and Genomics (ACMG) have guidelines for genetic
testing of minors. With regards to predictive testing of minors for adult-onset conditions, the
professional organizations all acknowledge potential concerns, such as possible stigma,
discrimination, loss of autonomy, or anxiety; however, they vary slightly in their
recommendations. The American Academy of Pediatrics (AAP), ACMG, and ASHG take a
strong stand on the deferral of testing with the exception of medical necessity during
adolescence, while NSGC is less cut and dried in their recommendation. If a minor is undergoing
sequencing, a lab may feel an obligation to analyze and interpret the genomic data for pathogenic
variants for the 59 medically-actionable genes recommended by the ACMG, which are
responsible for 24 conditions, some of which are adult-onset (Kalia et al., 2017). As a result,
there was a tension between two ACMG-supported guidelines—minors should postpone
predictive testing for adult-onset conditions and the requirement to return secondary findings on
a sequencing result regardless of age (Clayton et al., 2014). However, the ACMG has updated
their recommendations to give parents the opportunity to opt-out of secondary findings for their
children, if they wished to do so (Kalia et al., 2017). NSGC recommends that, if possible, testing
be deferred until a time at which the individual who is being tested has the capacity to
understand the weight and process the decision to be tested. This recommendation does not bar
the testing of an adolescent or other minors if conditions warrant it (“National Society of Genetic
Counselors: Position Statement: Genetic Testing of Minors for Adult-Onset Conditions,” 2017).
Although ASHG recommends deferring testing for adult-onset conditions until adulthood, they

recognize the potential for earlier testing in the context of relieving psychosocial distress and
making life-planning decisions (Botkin et al., 2015). While the professional organization
guidelines provide a guide for healthcare professionals, it is based on limited data summarizing
clinical experience and there remains questions to be answered that will require continued
reevaluation with the growth of genetic testing.
Consent vs. Assent
In most settings, the legal age for decision making is 18 years old. However, legal and
ethical policy guidelines encourage caregivers to help minors take on a greater role in decisionmaking regarding their health when they are competent to do so (Botkin et al., 2015).
Competence has been defined by three main capacities: “(1) to process and communication, (2)
to reason and deliberate, (3) to develop and sustain moral values” (Botkin et al., 2015). The
capacity of a child to give consent vs. assent is driven by their cognitive ability. In the United
States, children can begin being involved in decision-making by age 7 and thus can provide
“assent” to participate in research from that time on (Botkin et al., 2015). Assent only requires a
basic understanding of risk and benefit, while consent requires the ability to make independent
decisions. Consent becomes possible around the time of adolescence when minors have begun to
connect the present with the future and understand the long-term effects of decision-making to
some degree. This is thought to be around age 12-14. In adolescence, experts argue, minors are
still very malleable and can be influenced by a variety of factors including self-image, family
pressures, and stigmatization. (Botkin et al., 2015). The AAP statement on testing of minors
asserts that for predictive testing, the assent of the child should be sought and stresses that the
results of the test are ultimately theirs (Clayton, 2015).

Risks of Testing Minors for Adult-Onset Conditions
In the bioethics literature, there are three main arguments against testing minors for adultonset conditions: lack of respect for the child’s autonomy and their right not to know, concerns
about breaching the child’s confidentiality, and the potential psychological harm (Aatre & Day,
2011; Duncan et al., 2008; Malpas, 2008; Mand, Gillam, Delatycki, & Duncan, 2012). Among
the possible harms that have been discussed are distress, anxiety, and depression with the return
of a positive result (Aatre & Day, 2011; Bradbury et al., 2016). Some experts have raised the
possibility of vulnerable child syndrome and survivor guilt (Aatre & Day, 2011; Bradbury et al.,
2016; Mand et al., 2012). Overall, potential adverse emotional outcomes include altered selfesteem, feelings of blame, stigma, discrimination, and difficulty forming or maintaining
relationships with family and peers (Aatre & Day, 2011; Bloch & Hayden, 1990; Bradbury et al.,
2016; Mand et al., 2012; Wade, Wilfond, & Mcbride, 2010). All of these feelings might
reasonably be expected to tie into the child’s maturity level but, to contrary, Duncan et al. found
that many of the harms described by adolescents were not much different than those experienced
by adults (2008).
Benefits of Testing Minors for Adult-Onset Conditions
Counter arguments have been made to refute the idea that testing minors for adult-onset
conditions is problematic. Parents, it has been pointed out, can be expected to act in their child’s
best interests (Mand et al., 2012; Rhodes, 2006). Furthermore, adolescents are often more than
capable of making decisions regarding their own health (Borry, Goffin, NYS, & Dierickx, 2008).
Rhodes goes on to argue that the issue of confidentiality is moot because parents already bear the
responsibility of their child and make medical decisions on their behalf (2006).

As for psychological harm, Rhodes found in a 2006 study that after a brief period of
adjustment to the information, there was little to no harm (Rhodes, 2006). The argument for
testing assumes that testing may be beneficial because it promotes knowledge and a sense of
control and empowerment in the individual and, in turn, offers them a realistic expectation of
their prognosis with the condition (Malpas, 2008; Mand et al., 2012). In some studies, children
who have been tested have been found to have higher self-esteem in the context of both positive
and negative results (Aatre & Day, 2011; Mand et al., 2012; Rhodes, 2006). Bradbury et al.
found that girls with a positive BRCA1 or BRCA2 result and family history had higher selfesteem than those without the family history; this was found to be correlated with lower maternal
anxiety, strong communication within family, and having prior exposure to the condition (2016).
Huntington’s Disease
Huntington’s Disease is an adult-onset neurodegenerative disorder that has an autosomal
dominant pattern of inheritance. Individuals who carry an expansion of 36 or more CAG
trinucleotide repeats in one of their HTT genes will inevitably develop severe and progressive
motor, cognitive, and psychiatric disturbances. Currently, there are no effective treatments for
HD and the median survival time is 15-18 years after onset, which typically occurs during the
3rd or 4th decade of life. To date, care remains mainly supportive (Warby, Graham, & Hayden,
1993). Genetic testing for HD is extremely accurate. Pre-symptomatic testing is accompanied in
most medical centers by a team-based, pre-test protocol including psychiatric and neurologic
evaluations and genetic counseling. It is generally not easily available to minors (Huntington’s
Disease Society of America, 2016; MacLeod et al., 2013).
One study that included 480 adults who had not previously been clinically diagnosed
with HD but had either a positive genetic test or family history of the disease found that almost

half (46 %) of respondents reported genetic discrimination or stigma based on their genetic status
and/or family history of HD (Erwin et al., 2010). The highest proportion of discrimination and/or
stigma was described as related to insurance and relationships (Erwin et al., 2010). Within this
study, they discussed how it is currently not understood to what extent genetic stigma and/or
discrimination has an impact on daily life decisions. As such, there is little understanding of the
potential impact that genetic stigma and discrimination could have on minors.
The Need for Adolescent Opinions
Currently, literature on the impact of predictive testing of minors for adult-onset
conditions is very limited and consists mainly of research and opinion provided by healthcare
providers and bioethicists. The perspective of the minors themselves is absent from the debate.
This study is part of an ongoing analysis of the essays from the ASHG 2016 International DNA
Day essay competition, which provide a unique opportunity to hear from adolescents on their
opinions on genetic testing of minors for adult-onset conditions. The present study focuses on a
subgroup of those essays which discuss Huntington’s Disease.
MATERIALS AND METHODS
In Phase one of this study, a mixed-methods approach was developed to analyze essays
written by high school students submitted to ASHG’s annual 2016 International DNA Day Essay
Contest. The essay prompt for 2016 was as follows:
“Choose a genetic test that is currently available for a condition or disease that
does not cause symptoms until adulthood (i.e., an adult-onset condition such as
hereditary breast cancer). Describe how the test works and how certain the test
results are. Then, either defend or refute the recommendation below from ASHG’s
recent position statement on pediatric genetic testing. “Adolescents should be

encouraged to defer predictive or pre-dispositional testing for adult-onset
conditions until adulthood because of the complexity of the potential impact of the
information at formative life stages.”
The high school students were informed that their submissions might be used for research. Phase
one of this project received an exemption from the Sarah Lawrence College Institutional Review
Board (IRB) in April 2016 and Phase two received an exemption from the same body in October
2017. Approval was also sought and received from the Geisinger Health System IRB in March
2016.
All essays were initially categorized based upon demographic information (grade, gender,
country), which disease the individual chose to write about, and whether they chose to agree with
the ASHG statement (defer testing), disagree (not defer testing), or did not clearly state at
opinion (other). A code book was developed with the intention of investigating reasons why
minors would defer or not defer genetic testing for adult-onset diseases. The final code book
consisted of 25 universal codes that were used to analyze the essays in the qualitative analysis
program Atlas.ti (www.atlasti.com).
Code

Description

Psychological benefits to
minor

Benefits of knowing or not knowing their own genetic
information

Psychological risks to minor

Risks of knowing or not knowing their own genetic
information

Genetic testing accuracy and
predictability

High accuracy of genetic testing due to detection rate,
reliability, validity, predictability, technological accuracy

Genetic testing variability and
uncertain predictability

Limitations of genetic testing due to low detection rate,
reliability, validity, predictability, technological accuracy
(low genotype to phenotype predictability)

Factual genetic/disorder
information

Facts about genetics/the disorder that they chose to write
about

Incorrect facts

Any facts that are used in the essay that are incorrect

Risks to family

Possible negative effects of knowing or not knowing the
genetic information would have on family members

Benefits to family

Possible negative effects of knowing or not knowing the
genetic information would have on family members

Personal experience with the
condition

Mention of personal experiences with the disorder described
(themselves or family members) that influences their opinion
on testing or not testing

Personal experience with
genetic testing

Mention of personal experiences with genetic testing
described (themselves or family members) that influences
their opinion on testing or not testing

Medical benefit/prevention

Possibility of medical prevention or benefit that comes with
testing for the condition

No medical benefit/prevention

Lack of medical prevention or benefit that comes with testing
for the condition

Disrupts formative years

The right to be a child/have a normal adolescence.

Social risks

Negative changes in any social relations such as friends,
colleagues, and schoolmates

Social benefits

Positive changes in any social relations such as friends,
colleagues, and schoolmates

Mature and capable

Minor’s ability to adapt, handle, fully process the information

Immature and incapable

Neurological, emotional, and/or social immaturity

Potential discrimination

Any discrimination in career, insurance, social, stigma.

Necessary to plan/prepare

Genetic testing is necessary to plan for future as a minor

Unnecessary to plan/prepare

Genetic testing is unnecessary to plan for future as a minor (at
this time)

Advancements in science

Altruism or altruistic intent/contribute to research

Case-by-case

Suggestion to take each genetic testing case individually
(indicating that there are some instances when it is and is not
appropriate)

Loss of autonomy

Child’s inability to provide informed consent. Should not be
pressured, voluntary.

Individual’s choice

The opinion of the minor should be upheld over anyone else

Family/parent’s choice

The opinion of the minor/s family/parents should be upheld
over anyone else

Of the 1241 essays submitted, 77 were discarded as unfit for coding, including those that
did not address the prompt or focused on a different topic, were illegible or unintelligible, did not
state an opinion, or misinterpreted the question or ASHG policy.
In order for the coders in Phase one of the project to reach inter-rater reliability (IRR),
five essays were coded by each coder separately, and then compared. This process was repeated
until an IRR ≥ 75% was reached, and then the remaining HBOC, AD, and Lynch Syndrome
essays were divided evenly between the four group members for coding.
The most common disorders discussed in these essays were Huntington Disease (HD),
Alzheimer’s Disease (AD), and Hereditary Breast and Ovarian Cancer (HBOC). In Phase one, all
essays with an HBOC or Alzheimer’s Disease theme were coded, analyzed, and discussed. All
essays discussing Lynch syndrome (13 in total) were also thematically coded but not included in
the final analysis.
The focus of Phase two of the study was the coding and analysis of themes emerging in
the essays written about HD. An IRR of 82.9% was established between four new coders in the
same manner as described above. In addition, five previously coded essays from the Phase one
data set were blindly coded by each new group member and subsequently compared to one
another as well as the previous codes in order to establish if IRR between the Phase one and
Phase two coders. A collective IRR (between the coders from Phase one and two combined) of
76.5% was established.

Figure 1. The process of reaching inter-rater reliability (IRR) between coders in Phase one
and two
A total of 467 HD essays were equally divided among the four group members for
coding. The Phase one universal codebook was adopted in full with no changes to the 25 codes.
All essays had been previously uploaded to Atlas.ti and were coded using this program.
Upon completion of initial coding of the HD essays, data was downloaded from Atlas.ti
to Excel spreadsheets. Included in these data sets were totals of top codes used as well as a list of
the exact quotes used for these codes. Top five codes used were established to be: “Factual
Genetic/Disorder Information”, “Necessary to Plan/Prepare”, “Genetic Testing Variability and
Uncertain Predictability”, “No Medical Benefit”, and “Psychological Risks to Minor.” All five of
these codes, except for “Factual Genetic/Disorder Information”, were further analyzed for
themes by reading through the quotes pulled from the respective essays. “Factual
Genetic/Disorder Information” was excluded from the additional analysis for themes because
this information was required to be included in the essays and offered no further insight into their
reasoning behind whether they agreed or disagreed with the ASHG recommendation. Each of the

other main codes were analyzed further for specific themes. Themes were counted and organized
into tables of their own. All final counts accounted for the number of unique essays that used a
particular theme within a code. For example, one essay might have used one code three times,
but only addressed two themes. This essay would be counted twice in the tables, one for each
theme. The essay was the unit of analysis, and the number of themes per essay was quantified to
illustrate any thematic similarities or differences between defer and non-defer arguments.
RESULTS
Of the 1241 student essays submitted to the 2016 ASHG DNA Day Essay Contest, 467
essays were about Huntington’s Disease. Out of these 467 essays, 266 chose to “Defer” testing,
163 essays chose to “Not Defer” testing, and 38 essays cited “Other” or “None” on testing
opinion. Table I illustrates how the Huntington’s Disease essays were broken down by testing
choice. Table II shows the demographics of the 429 “Defer” and “Not Defer” essays, broken
down by gender and grade level.
Testing Choice Number of Essays % of Total Essays
Defer

266

57%

Not Defer

163

35%

Other/None

38

8%

Table I. Testing choices of the 467 Huntington’s Disease essays

Demographics

% that
Deferred

% that Not Deferred

Female

64%

36%

Male

58%

42%

9th Grade

63%

37%

10th Grade

58%

42%

11th Grade

69%

31%

12th Grade

59%

41%

Table II. Demographics of the 429 Huntington’s Disease essays that chose to “Defer” and “Not Defer” testing

Table III describes the top five codes utilized in the Huntington’s Disease essays and the
number of quotes associated with each code.
Code

Number of Quotes

Factual Genetic/Disorder Information

817

Psychological Risks to Minor

526

No Medical Benefit or Prevention

341

Necessary to Plan and Prepare

340

Genetic Testing Variability & Uncertain Predictability 191
Table III. Top five codes used in the Huntington’s Disease essays

Psychological Risk to Minor
The code “Psychological Risk to Minor” was used 526 times in essays. This code was
defined in the codebook as statements that describe an increase in the adolescent’s anxiety,
depression, apathy, fear, helplessness, devastation, or loss of self-esteem, as well as statements
about risky behavior, self-harm and suicide. This code was used to describe any psychological
consequences that may arise due to the decision to pursue or to not pursue genetic testing for
Huntington’s Disease. The themes present within this code were General psychological risk to
minor, Anxiety, Depression, Self-harm/suicide, Harm self-esteem, Harm development, Substance
abuse, Survivor’s guilt, Hopelessness, and Helplessness. “Psychological Risk to Minor” was split
into the following four testing scenarios: (1) pursuing genetic testing and receiving a positive
result, (2) pursuing genetic testing and receiving a negative result, (3) pursuing genetic testing in
general, and (4) not pursuing genetic testing. These scenarios were then subdivided into essays

that chose to defer or not defer testing. The frequency of use for each theme is displayed in Table
IV.
Psychological risk to a minor when receiving a positive genetic testing results for
Huntington’s Disease was the most commonly discussed scenario, showing up 389 (74.0%)
times. Of the 389 essays which discussed this topic, 331 (85.1%) of these essays chose to defer
testing, while 38 (9.8%) chose to not defer, and 20 (5.1%) did not clearly specify. Of the essays
which chose to defer, the most common themes were Psychological risk to minors in general
(31.7%), risk for Depression (21.1%), and the risk for Anxiety (19.3%).
The second most common scenario was the psychological risk to a minor when pursuing
genetic testing for Huntington’s Disease in general, without specifying the outcome of the
results. This was discussed 113 (21.5%) times. Out of the 119 times this topic was discussed 92
(77.3%) chose to defer, 17 (14.3%) chose to not defer and 4 (3.4%) did not specify.
All but one essay which discussed negative test results and chose to defer (91.7%) used
the theme Survivor’s guilt.
Overall, the three most commonly used themes were Psychological risk to minor in
general (47.8%), risk for Anxiety (20.7%), and risk for Depression (12.0%).

Theme

Positive Test Results

Negative Test
Results

Testing in General

Not Testing

Defer

Not
Defer

Othe
r
/None

Defer

Not
Def
er

General

105
(31.7
%)

7
(18.4
%)

6
(30.0
%)

0

Anxiety

64
(19.3
%)

10
(26.3
%)

4
(20.0
%)

1
(8.3%
)

Total

Oth
er
/No
ne

Defer

Not
Defer

Othe
r
/None

Defer

Not
Defer

Oth
er
/No
ne

0

0

44
(47.8
%)

8
(47.1%
)

2
(50.0
%)

1
(50.0
%)

5
(50.0
%)

0

178
(33.8
%)

0

0

19
(20.7
%)

3
(17.6%
)

1
(25.0
%)

1
(50.0
%)

2
(20.0
%)

0

105
(20.0
%)

Depressio
n

70
(21.1
%)

11
(29.0
%)

4
(20.0
%)

0

0

0

11
(12.0
%)

3
(17.6%
)

0

0

2
(20.0
%)

0

101
(19.2
%)

SelfHarm
/ Suicide

31
(9.4%
)

4
(10.5
%)

4
(20.0
%)

0

0

0

4
(4.3%
)

2
(11.8%
)

0

0

0

0

45
(8.6%
)

Harm
Self
Esteem

17
(5.1%
)

2
(5.3%
)

1
(5.0%
)

0

0

0

4
(4.3%
)

1
(5.9%)

1
(25.0
%)

0

1
(10.0
%)

0

27
(5.1%
)

Harm
Developm
ent

17
(5.1%
)

0

0

0

0

0

3
(3.3%
)

0

0

0

0

0

20
(3.8%
)

Substance
Abuse

14
(4.2%
)

0

0

0

0

0

6
(6.5%
)

0

0

0

0

0

20
(3.8%
)

Survivor'
s Guilt

1
(0.3%
)

2
(5.3%
)

1
(5.0%
)

11
(91.7
%)

0

0

0

0

0

0

0

0

15
(2.9%
)

Hopelessn
ess

9
(2.7%
)

1
(2.6%
)

0

0

0

0

1
(1.1%
)

0

0

0

0

0

11
(2.1%
)

Helplessn
ess

3
(0.9%
)

1
(2.6%
)

0

0

0

0

0

0

0

0

0

0

4
(0.8%
)

Total

331

38

20

12

0

0

92

17

4

2

10

0

526

Table IV. Psychological Risk to Minors and its Themes

Figure 2. Psychological Risks and its Themes

No Medical Benefit/Not Preventable
The code “No Medical Benefit/Not Preventable” was defined within the codebook as a
discussion of the lack of benefit or prevention. This code was used with statements that describe
no treatments or prevention to stop the development of the disease or to cure the disease and the
lack of available screening to minors. The essays that were coded as “No Medical Benefit/Not
Preventable,” were then subcoded for themes. The themes included Ineligible for clinical trials,
Limited treatment options, No changes in medical intervention as child, No cure, No indication
of disease course, No indication of disease onset, No prevention, No treatment, Treatment side
effects, and Treatment can’t slow down /stop illness. Among the essays coded, the themes No
cure and No treatment were most common (Table V).
The theme No Cure was the most common theme in both the “Defer” and “Not Defer”
essays. In the “Defer” essays, the No cure theme was used 42% of the time and in the “Not
Defer” essays, it was used 60% of the time. No treatment was the second most common theme
under the code “No Medical Benefit/Prevention.” In the “Defer” essays, the No treatment theme
was used 19% of the time and in the “Not Defer” essays it was used 11% of the time.
Theme

Defer

Not
Defer

Other/None Total

Ineligible for clinical trials

3 (1.8%) 0

0

3 (1.2%)

Limited treatment options

3 (1.8%) 2 (3.5%)

0

5 (2.0%)

No changes in medical intervention as 1 (0.5%) 0
child

0

1 (0.4%)

No cure

72
(42%)

9 (45%)

115
(46.5%)

No indication of disease course

5 (2.9%) 0

0

5 (2.0%)

34 (60%)

No indication of disease onset

6 (3.5%) 1 (1.8%)

0

7 (2.8%)

No prevention

23
(14%)

5 (9%)

1 (5%)

29 (11.7%)

No treatment

33
(19%)

6 (11%)

5 (25%)

44 (17.8%)

Treatment side effects

1 (0.5%) 1 (1.8%)

0

2 (0.8%)

Treatments can't slow down/ stop
illness

23
(14%)

8 (14%)

5 (25%)

36 (14.5%)

Total

170

57

20

247

Table V. No Medical Benefit and its Themes

Figure 3. No Medical Benefit and its Themes

Necessary to Plan/Prepare
The code “Necessary to Plan/Prepare” was defined within the original codebook as
“genetic testing is necessary to plan for future as a minor.” This code was used with statements
that describe the necessity of obtaining their genetic information in order to adequately plan and
prepare for future aspects of one’s life. The quotes that were coded as “Necessary to
Plan/Prepare,” were then analyzed for themes. The themes that emerged from this code included:
Making proper financial/emotional arrangements before getting sick, Family

planning/reproductive purposes, General planning/preparing for one’s future, and Accomplish
goals/have meaningful life before disease onset.
The two most common themes for this code are Making proper financial/emotional
arrangements before sick and Family planning/reproductive purposes. These themes accounted
for 40% and 38%, respectively, of the 255 essays in which this code was used (including defer,
not defer, and other/none). The majority of essays expressing the Making proper
financial/emotional arrangements before sick theme were “Not Defer” essays (72 versus 20
“Defer” essays). This was similar for the Family planning/reproductive purposes theme, where
67 were “Not Defer” and 24 were “Defer”. The vast majority of essays using the code
“Necessary to Plan/Prepare” were “Not Defer” essays (181 of 255 or 70.9%), regardless of the
theme (Table VI).
Theme

Defer

Not
Defer

Other/None

Total

Making proper financial/emotional
arrangements before sick

20
(34.5%)

76
(42.0%)

6 (37.5%)

102
(40%)

Family planning/reproductive purposes

24
(41.4%)

67
(37.0%)

5 (31.3%)

96
(38%)

General planning/preparing for one’s
future

9
(15.5%)

18
(9.9%)

3 (18.8%)

30
(12%)

Accomplish goals/meaningful life before
disease onset

5 (8.6%)

20
(11.0%)

2 (12.5%)

27
(11%)

Total

58

181

16

255

Table VI. Necessary to Plan/Prepare and its Themes

Figure 4. Necessary to Plan/Prepare and its Themes

Genetic Testing Variability and Uncertain Predictability
The code “Genetic Testing Variability and Uncertain Predictability” was defined in the
original codebook as: “Limitations of genetic testing; detection rate, reliability, validity,
predictability, technological limitations (unclear genotype to phenotype correlation).” This code
was used with statements that described the genetic testing for Huntington’s Disease as
uncertain, inaccurate, or unable to predict the onset or symptoms of the condition. The themes
within this “Genetic Testing Variability and Uncertain Predictability” code were Intermediate
range of repeats, Not 100% accurate/certain, Uncertain predictability of symptoms, and
Inconclusive results.
The most common theme was Uncertain predictability of symptoms, which made up
about 46% of all the essays that used “Genetic Testing Variability and Uncertain Predictability”
code. The same theme was also the most prevalent in both the “Defer” and “Not Defer” essays
with 45% and 50% of the essays, respectively. In the “Other/None” essays, the most common
theme used was Not 100% accurate/certain, accounting for 57% of those essays. Table VII lists

the proportion of “Defer”, “Not Defer”, and “Other/None” essays that fall under the various
themes.
Theme

Defer

Not
Defer

Other/None

All

Intermediate range of repeats

32 (26%)

17 (31%)

1 (14%)

50 (27%)

Not 100% accurate/certain

36 (29%)

9 (17%)

4 (57%)

49 (26.5%)

Uncertain predictability of
symptoms

56 (45%)

27 (50%)

2 (29%)

85 (46%)

0

1 (2%)

0

1 (0.5%)

124

54

7

185

Inconclusive results
Total

Table VII. Genetic Testing Variability and Uncertain Predictability and its Themes

Figure 5. Genetic Testing Variability and Uncertain Predictability and its Themes

DISCUSSION
Psychological Risk to Minor
Limited research so far has not found an increase in psychological risk with testing;
however, this was the second most discussed theme in the essays discussing HD in this study

(Wade, Wilfond & McBride, 2010). Overall, students appear to use potential psychological risks
as a key deciding factor in their argument whether to defer or not defer testing.
Some students had concerns regarding the potential psychological risk, as demonstrated
by one student who stated, “The results of testing positive could have major effects on the
emotional stability of the adolescent” (Essay 667, Defer), but did not delve into the specifics.
Other students went further in elaborating details of psychological harm. For example, one
student stated, “Knowing one's test results at a young age can result in anxiety, behavioral
issues, depression, lessened self-esteem and independence” (Essay 1236, Defer). Most students
used the natural history, clinical features and the lack of treatment for HD to identify causes for
the psychological risk. Students referred to HD resulting in early death as an argument both for
and against testing. As stated by a few students, “the prospect of a confirmed early death could
have enormous psychological ramifications on individuals positive for HD” (Essay 456, Defer),
most often noted as an increase in anxiety and depression, and “would have a devastating effect
on [a person’s] quality of life” (Essay 204, Defer).
Students who argued for not deferring testing often also recognized the psychological
risks that could arise due to a positive result, “The simple knowledge that the disease will one day
be active can hugely impact one’s life and bring forth many emotional consequences. Learning
about it at a young age may cause huge amounts of fear, anxiety, depression, stress” (Essay
1202, Not Defer). Individuals who chose to not defer testing, while they cited psychological risks
associated with testing, many also considered the potential benefits.
Although a majority of essays discussing psychological risk to minors pursuing genetic
testing for HD had stated concerns with receiving a positive HD test result, some students also
dove into the possible psychological implications of receiving a negative test result and the risks

associated with not pursuing testing. Students were able to dissect the complexities associated
with both testing and not testing for a degenerative neurological disorder. All but one student
who discussed psychological risk in respect to receiving a negative test result brought up the
possibility of survivor’s guilt. One student described survivor’s guilt as “feel guilty for escaping
the disease that other members of the family suffer from” (Essay 956, Not Defer). Another
student demonstrated the complexities of their thoughts by contrasting these potential risks. “The
result of the HD test may be enough to push the patient into depression and place a heavy
burden on them. After disclosure of the results, people were found more likely to succumb to
depression and hopelessness. Those who believed that their results were going to be normal
experienced many difficulties after knowing their result was positive. Alternatively, those who
found that their result was negative also experienced survivor’s guilt if a relative’s result
happened to be positive” (Essay 879, Defer).
Anxiety and Depression were present in both arguments made for and against deferring
genetic testing. These themes were brought up in the context of eventually knowing one will
develop HD status from a positive test result as demonstrated by the following statement,
“Realistically, the frustration and helplessness derived from the idea that the deterioration of
their lives is inevitable would likely lead to depression and anxiety” (Essay 1153, Defer). Anxiety
was also brought up in the context of not knowing what the future holds by not pursuing genetic
testing, “deferring a genetic test for an adolescent suspected of carrying a disease places
uncertainty on that individual, which results in negative emotional effects such as excessive
worrying and anxiety” (Essay 1094, Not Defer). Many students acknowledged that regardless of
if they agreed or disagreed with ASHG’s position statement, there were potential psychological
consequences.

No Medical Benefit/Not Preventable
The most common theme used in all HD essays was No cure. The discussion found in
essays where students argued to not defer testing for HD commonly discussed potential
treatment, “There is no cure for Huntington’s Disease (HD) but there are treatments to reduce
its symptoms” (Essay 636, Not Defer). In the “Not Defer” essays, students often discussed the
lack of cure, but then commented on the availability of treatments. “Even though a cure has yet
to be discovered, there are steps that can be taken to slow down the progression of the disease”
(Essay 1146, Not Defer). This was in contrast to the discussion found in essays where students
argued to defer testing, the No cure theme was often used in the context of death, “HD is fatal,
and there is no cure” (Essay 585, Defer). In some of the cases, there appears to be a lack of
knowledge about the availability of treatment, “As this is a fatal disease with no cure, receiving a
positive test is sometimes seen as a death sentence” (Essay 387, Defer). Even in situations where
the students acknowledged the availability of medical treatment, the fatality of the condition was
discussed in essays where the student encouraged deferral, “There are some medications for
Huntington’s disease, but, ultimately, none of the medications can completely prevent the
symptoms or the imminent death caused by the disease” (Essay 498, Defer). This contrast in the
way in which the No cure theme was used in “Defer” and “Not Defer” essays suggests that there
are some students who felt that the therapies were good enough to warrant testing, while others
were either unaware of therapies and/or felt that the current treatment is insufficient at this time
for them to pursue genetic testing.
Another common theme within the code, “No Medical Benefit/Not Preventable,” was
Treatments can’t slow down/stop illness. This was the second most common theme in essays that
chose to not defer testing for HD, whereas it was fourth most common theme in essays that chose

to defer testing for HD. In the “Not Defer” essays, the theme Treatments can’t slow down/stop
illness was used in a much more hopeful manner, “No treatments of our generation are able to
alter or slow the effects of Huntington’s disease” (Essay 897, Not Defer). This student was
discussing the lack of treatment, in the context of the current “generation,” which implied that
there might be changes in the future generations. Another “Not Defer” essay said, “as of now,
there is no treatment that can alter the course of Huntington's disease” (Essay 806, Not Defer).
Several of the students referenced the treatments in the context of current time, implying that
there is hope for future improvements to treatment, “As of today, there are no treatments that
have the capability of curing the fatal disease” (Essay 367, Not Defer). This may represent how
some students showed dispositional optimism with regards to the future of medicine, while
others focused more on the risks. Some research has found that individuals who are high in
optimism are actually more knowledgeable about risk factors than those who had less optimism
(Carver et al., 2014). A student who chose to defer testing wrote, “Maybe someday, when there
are treatments for HD, adolescents should be tested in hopes of being able to fight the disease
before it attacks. But currently, there are none” (Essay 1226, Defer). Interestingly, this student
who wrote in favor of the deferral of testing, recognized that there is some hope from
improvements in treatment, but they feel that testing should be deferred until such time. In
comparison, in the essays that chose to defer testing, many of the students used this code in
conjunction with the psychological risk to minors, “However, since there is currently no way to
prevent, cure, or slow the progression of this disease, testing a child may cause more harm than
good, for both the child and the parents” (Essay 480, Defer). Another student wrote,
“determining early in life that the child will develop HD later on does not benefit them in any
way since there is no treatment that can reduce the risk or change a child’s outcome of

developing HD” (Essay 841, Defer). Students who wrote in favor of deferring testing often wrote
about how there is no benefit, but rather a risk to the child, since there is currently no treatment
available.
Necessary to Plan/Prepare
The variety in themes that emerged under the “Necessary to Plan/Prepare” code
illustrated the depth of insight these minors have with regards to their future. The majority of
writers who discussed this concept chose to argue in favor of not deferring testing until
adulthood, suggesting that they think the information gained through genetic testing for HD is
valuable during their teen years. This is a time in their life where they are already planning for
things, such as starting a family and accomplishing long term goals. Even though these minors
are children in the eyes of some, they are already beginning to speculate what a future family
might look like for them and how to best plan for the genetic health of that family, “Also, having
the understanding of the possibility of developing a hereditary disease would prepare
adolescents ahead of time of the risk of passing on the faulty HD gene to their own offspring.
This prior knowledge could assist adolescents, later in life, when making decisions concerning
conception” (Essay 705, Not Defer).
In addition to family planning, minors expressed the desire to adapt their life goals and
financial situation to best suit their future health. Even students who argued overall to defer
testing still acknowledged its potential benefits in adolescence, “a negative result would provide
reassurance, whereas a positive result would allow for more realistic goals” (Essay 450, Defer).
Another writer stated, “Adolescence is in fact a superior time to discover such as disease
because more time is available for planning, whether social, personal, or especially financial”
(Essay 609, Not Defer).

Genetic Testing Variability and Uncertain Predictability
It is well-known in the medical community that the genetic test for HD is highly accurate,
and a positive result almost certainly means that an individual will develop symptoms of HD in
the future. Despite this inevitability, the test cannot predict when the symptoms will begin.
Interestingly, roughly half of the “Defer” and “Not Defer” essays that used the code “Genetic
Testing Variability and Uncertain Predictability” discussed Uncertain predictability of
symptoms. Most of the time, the students talked about how the test cannot predict the age of
onset, the severity of the symptoms, or the progression of the disease, “However, genetic testing
cannot determine when the symptoms will develop in their intensity and severity” (Essay 378,
Not Defer). No one identified this as the main reason why they chose to “Defer” or “Not Defer.”
It was mainly used as factual information to describe the genetic test for HD.
The theme Intermediate range of repeats, similar to Uncertain predictability of
symptoms, was mainly used to describe the genetic test for HD and what it entailed. In this
theme, individuals talked about how the 36 to 39 repeat range was considered the gray area,
where it is unknown if someone would be affected in the future. Quotes from this theme often
also cited the unpredictability of the symptoms, but more in terms of whether or not someone
would truly be affected, rather than the uncertainty of the onset of symptoms, “There is some
uncertainty with the HD DNA testing; for example, some individuals with CAG repeats from 3639 never develop symptoms for HD, while others develop symptoms” (Essay 1074, Defer). Only
about half the essays that used this theme also mentioned that getting this uncertain result is rare
and only happens in about 1% of cases. Interestingly, a couple of essays used this uncertain
result to determine that the test is not accurate, “Some people with counts between thirty-five and
forty have developed Huntington’s and others have not, so such a count is considered an

inconclusive result. This gray area means that the test is not entirely accurate” (Essay 1201,
Defer). They interpreted test accuracy in terms of sensitivity rather than as a measure of the test
correctly calling the number of repeats.
Of the essays that used the code “Genetic Testing Variability and Uncertain
Predictability,” about 29% of the “Defer” essays and 17% of the “Not Defer” essays cited the
theme Not 100% accurate/certain. Although the genetic test for HD is highly accurate, many
essays focused on the fact that the test is not 100% accurate, citing human and technical errors
that may occur, “This genetic test for HD is 98-99% accurate, leaving one or two percent chance
of inaccuracy only due to the possible, unavoidable errors that may occur in laboratory
procedures” (Essay 552, Defer). There might be confusion about the definition of accuracy
because some essays described how the test is not accurate because it is not truly predictive and
only provides an increased risk of developing HD, “Several genetic tests can only give a
possibility for a condition and not full certainty, making them unreliable” (Essay 322, Defer).
Many of the “Defer” essays that had the theme Not 100% accurate/certain used it as one of their
reasons to defer testing, “Another example of unnecessary stress due to premature testing is
worrying despite the possibility that one will not develop Huntington’s at all. Even though the
test is reliable, it is not 100 percent accurate” (Essay 364, Defer).
Limitations
The ASHG DNA Day essays used in this study were a convenience sample which had a
few limitations. While many of the essays were submitted from the United States, it is unclear
whether essays were self-submitted or a teacher assigned this to the entire class and handselected the best ones to submit. As discussed in Phase one of this study, there were disparities in
the demographics of this data. Females represented 67% of the submissions and although 87% of

submissions were from the United States, not all states were represented equally and some were
not represented at all; thus, this was not representative of all adolescents.
CONCLUSIONS
Adolescents were split as to whether or not genetic testing for HD should be deferred
until adulthood, with a majority favoring deferral. Although they were required to argue for or
against deferring genetic testing for HD until adulthood, most students discussed similar points,
regardless of their stance. Many were able to consider their lifestyle, values, and goals in their
decision-making, but there were occasions when they misunderstood or were not fully aware of
specific information, such as medical management and test accuracy. This exemplifies the
importance of genetic counseling in the pre-test protocol to make sure that adolescents are wellinformed and mentally prepared to receive genetic testing results. Although many professional
organizations recommend the deferral of genetic testing for adult-onset conditions until
adulthood, there is some flexibility in the timing of testing minors on a case-by-case basis. In
order to provide assent for testing, adolescent perspectives must be considered to determine
whether the benefits of testing truly outweigh the risks.
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